Hjem › Diffust stort B-celle lymfom › New Jersey
Diffust stort B-celle lymfom kliniske forsøg i New Jersey
13 studier for Diffust stort B-celle lymfom søger deltagere på steder i New Jersey.
Byer i New Jersey
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Astera Cancer Care, East Brunswick
- John Theurer Cancer Center, Hackensack
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Atlantic Health Morristown Medical Center ( Site 0163), Morristown
- Valley Health Systems - Ridgewood Campus ( Site 0125), Paramus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Hackensack, Hackensack
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Hackensack Meridian Health (Data collection only), Hackensack
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- og 1 flere
RekruttererFase 2
Alder 65 til 80 · Alle køn · Opdateret 22. jul. 2026 · NCT06765317SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. apr. 2026 · NCT06544265Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 17. feb. 2026 · NCT04512716A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. dec. 2025 · NCT06736613Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Hackensack University Medical Center, Hackensack
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 26. sep. 2024 · NCT06238648Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.